Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORG33628
- Development stage
- Discontinued
- Lead developer
- Organon
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ORG33628 is a potent and selective small molecule progesterone receptor (PR) antagonist (antiprogestin) with high selectivity over the glucocorticoid receptor (GR). Originally developed by Organon, the compound was investigated in Phase II clinical trials for female contraception, specifically to improve cycle control and manage vaginal bleeding in progestin-only contraceptive regimens. However, development was discontinued because the combination compromised ovulation inhibition. ORG33628 has also been evaluated in preclinical models for its potential in breast cancer prevention and treatment, as well as other hormone-dependent conditions like uterine leiomyomas and endometriosis.
02
Targets
GR (Glucocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on ORG33628.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORG33628.